Lexeo Therapeutics

The European Commission recently granted orphan medicinal product designation to LX2006 for the treatment of Friedreich ataxia (FA).       This milestone reinforces our belief our investigational gene therapy, LX2006, has the potential to be transformative for people with FA. FA cardiomyopathy is a serious and life-threatening condition with no approved therapies. We look forward to working closely with the European Medicines Agency and other regulatory agencies to expedite our clinical development and delivering this therapy to patients across the globe. 

Our Lexeo team recently enjoyed an amazing summer event that truly captured the spirit of #OneLexeo. We kicked off the day with a memorable cruise around New York City, taking in the stunning skyline and creating wonderful memories together. But the celebrations didn't stop there! We also marked a significant milestone – our two-year anniversary at the 345 Park Avenue office. This special event brought together colleagues, office neighbors like Apertura Gene Therapy, along with various vendors and friends of Lexeo for a fantastic evening of camaraderie and celebration. A huge thank you to everyone who joined us and made these events unforgettable. Your dedication and collaboration are what make Lexeo such a special place to work. Check out the team photo from our NYC cruise below! PC: Christopher Ruetten

We're excited to highlight a recent paper in the European Heart Journal on the genetics of hypertrophic cardiomyopathy (HCM). The study reveals that pathogenic variations in cardiac sarcomere genes account for 30%-40% of HCM cases. This paper speaks to the importance of genetic testing to understand the underlying cause of the disease, diagnostic confirmation, and future family planning. Discover more here: https://lnkd.in/gw8Y7ZWn

Did you know arrhythmogenic cardiomyopathy, or ACM (also known as ARVC), is a heart disease where heart muscle is replaced by fibrotic tissue and fatty deposits? This can lead to heart dysfunction and abnormalities in cardiac rhythm. Half of the estimated 130,000 people living with ACM in the US have a genetic underlying cause. A mutation/pathogenic variant in the PKP2 gene is the most common genetic driver of ACM, affecting about 60,000 people, although mutations in other genes can cause ACM as well. To date, there are no approved therapies that address the underlying genetic cause of ACM. Lexeo's investigational gene therapy, LX2020, is currently being evaluated in a phase 1/2 clinical trial called HEROIC-PKP2 for PKP2-ACM. Learn more about LX2020, Lexeo’s gene therapy candidate for PKP2-ACM: https://lnkd.in/gNWDX9aQ

Today, we are pleased to share our second quarter 2024 financial results and recent corporate updates.   Visit our ‘News & Events’ page to learn more about our latest progress. https://lnkd.in/eBcSeAaq

Friedreich ataxia (FA) is a genetic disease that is caused by deficiency in the frataxin protein. Symptoms typically begin in childhood and impact the nervous system (such as impaired muscle coordination, movement issues) and the heart. As the disease progresses, most patients develop heart conditions such as hypertrophic cardiomyopathy and arrhythmias. Although cardiac complications are the leading cause of death in almost 2/3 of patients with FA, there is currently no approved treatment for the heart problems associated with FA. At Lexeo, we are developing LX2006 to address this significant unmet need to address these critical cardiac manifestations: https://lnkd.in/exYWF9U7

We're thrilled to introduce the bright minds joining us this summer!     Our interns play an important role in providing us with fresh perspectives, innovative ideas, and passion for science, all of which are invaluable to our team. Let's give a warm welcome to these future leaders! #OneLexeo 

We are thrilled to share that Jenny Robertson, our Chief Business and Legal Officer, will be participating in a panel discussion at the 11th Annual Summit for Women Leaders in Life Science on Lessons from Women Trailblazers in Life Sciences Law.    Join Jenny for an inspiring session designed to empower women at all career stages. She will share her valuable insights on shattering the glass ceiling, thriving at the executive level, and balancing professional and personal goals.     To learn more about the conference and its speakers, visit: https://lnkd.in/e8KRXTZc     #OneLexeo #WomenInLeadership

During #FAAwarenessMonth, our CEO Nolan Townsend and Jen Farmer, CEO of the Friedreich's Ataxia Research Alliance (FARA), sat down with Karen Jagoda on the Empowered Patient Podcast.     Together, they dove deep into Friedreich ataxia, its cardiac manifestations and clinical research that may provide hope for those living with FA.     Listen to the full episode here: https://lnkd.in/eM_zHqs5

We are proud to share positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across two clinical trials – the SUNRISE-FA Phase 1/2 trial sponsored by Lexeo and a Phase 1A Weill Cornell Medicine investigator-initiated trial – LX2006 was well tolerated with no treatment-related serious adverse events, and clinically meaningful improvements in cardiac biomarkers were observed with increasing improvement over time.   Read more here: https://lnkd.in/e2QD2YKA